Summit Therapeutics (SMMT) EBT Margin (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly EBT Margin came in at 8014.55% in Q3 2022, down 651730.0% YoY from N/an in Q3 2021, and down 41.13% on a QoQ basis from 5678.72% in Q2 2022.
Summit Therapeutics (SMMT) EBT Margin (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of EBT Margin data on file, last reported at 8014.55% in Q3 2022.
- Quarterly EBT Margin fell 651730.0% year-over-year to 8014.55% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 274831.82% (down 27079769.0% YoY) and the FY2022 annual result came in at 11174.75%, down 627691.0% from the prior year.
- EBT Margin fell to 8014.55% in Q3 2022, from 5678.72% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 91.21% in Q4 2019 to a low of 42835.09% in Q2 2021.
- A 5-year average of 6718.02% and a median of 5308.01% in 2019 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2021 — EBT Margin slumped 3373509 bps — and 2022, when it jumped 3715636 bps.
- Tracing SMMT's EBT Margin over 5 years: stood at 1393.93% in 2018, then surged by 107 bps to 91.21% in 2019, then slumped by 8137 bps to 7330.81% in 2020, then slumped by 47 bps to 10796.41% in 2021, then increased by 26 bps to 8014.55% in 2022.
- The last three EBT Margin figures came in at 8014.55% (Q3 2022), 5678.72% (Q2 2022), and 8982.0% (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -8,014.55% |
| Jun 30, 2022 | -5,678.72% |
| Mar 31, 2022 | -8,982.00% |
| Dec 31, 2021 | -10,796.41% |
| Sep 30, 2021 | -1,497.25% |
| Jun 30, 2021 | -42,835.09% |
| Mar 31, 2021 | -9,108.33% |
| Dec 31, 2020 | -7,330.81% |
| Sep 30, 2020 | -9,833.70% |
| Jun 30, 2020 | -9,100.00% |
| Mar 31, 2020 | -2,365.52% |
| Dec 31, 2019 | 91.21% |
| Oct 31, 2019 | -6,255.65% |
| Sep 30, 2019 | -4,233.11% |
| Jul 31, 2019 | -4,937.30% |
| Mar 31, 2019 | -1,645.07% |
| Oct 31, 2018 | -1,393.93% |
| Jul 31, 2018 | 71.46% |
| Apr 30, 2018 | -175.22% |
| Jan 31, 2018 | -340.33% |